There has been supportive evidence in large scale clinical trials, for example, the Canakinumab (a monoclonal IL-1β antibody) Anti-inflammatory Thrombosis Outcome Study (CANTOS), found that it significantly lowered the recurrence rate in patients post-myocardial infarction at residual inflammatory risk of CVD as indicated by C-reactive protein (CRP) levels >2 mg/L despite the standard treatment strategy [26]. This evidence concerns the gene CRP and myocardial infarction.